Dr. Guohui Han 韩国晖
Chief Physician, Associate Professor
Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast diseases, including radical mastectomy, breast-conserving surgery, reconstruction, surgery for benign lesions, adjuvant therapy, and salvage therapy for advanced breast cancer.
Dr. Han is Deputy Director (presiding) of the Breast Surgery Department at Shanxi Cancer Hospital, Chief Physician, and Master’s supervisor. With years of clinical experience, Dr. Han specializes in surgical and medical management of breast cancer and benign breast conditions.
Professional roles
- Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Breast Disease Professional Committee, China Medical Education Association
- Vice Chair, Breast Cancer Professional Committee, Shanxi Anti-Cancer Association
Name order: in Chinese the family name comes first (Han Guohui). Papers usually list the name as Guohui Han or Han G.
Selected publications
22 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int Immunopharmacol, 2026 (senior author): Ginsenoside Rh2 inhibits epithelial-mesenchymal transition in triple-negative breast cancer cell via disrupting the HIF-1α/YAP nuclear translocation axis. PubMed 42190415
- Cell Biol Toxicol, 2025 (senior author): Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer. PubMed 40000487
- Biochem Genet, 2024 (senior author): Circ_0059457 Promotes Proliferation, Metastasis, Sphere Formation and Glycolysis in Breast Cancer Cells by Sponging miR-140-3p to Regulate UBE2C. PubMed 37284894
- Heliyon, 2024 (first author): Long non-coding RNA HANR modulates the glucose metabolism of triple negative breast cancer via stabilizing hexokinase 2. PubMed 38192790
- Exp Ther Med, 2021 (first author): MicroRNA-598 inhibits the growth of triple negative breast cancer cells by targeting JAG1. PubMed 33603843
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion